Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

A highly contagious liver infection is surging among groups who are not typically at risk. At least seven people have died.

Symptoms and Treatment The liver is a vital organ in our body, playing a crucial role in digestion, detoxification, and ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...